Articles On Pharmaxis (ASX:PXS)

CEO Gary Phillips said, “We are confident that these results, if repeated in the whole study population, will satisfy regulatory requirements to continue the development of PXS-5505 in myelofibrosis and also excite clinicians"....

It’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own small portions of much larger things, you owe it to yourself to sit back and relax in front of a warm, crackling fire. So crack open a bott...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

ASX code: ((PXS)) Share price: 8.4 cents Shares on issue: 549,139,613 Market cap: $46.1m Chief executive officer: Gary Phillips Board: Malcolm McComas (chair), Mr Phillips, Dr Kathleen Metters, Dr Neil Graham Financials (full year to June 3...

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi...

Whether it’s two-for-one shopper docket deals or snaring a slightly used treadmill from the ‘free’ classification of Gumtree, we all like something for nothing and share market trading is no different. In the small to mid cap space, it’s po...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

The ASX healthcare index has fallen this week as a strong reporting season comes to a close with outlook still positive for FY23 Clinuvel Pharmaceuticals (ASX:CUV) jumps up more than 14% this week on positive FY22 results including revenue...

Pharmaxis gets ~$5m to collaborate on a Phase 2 study of lead drug, PXS‐4728. Imugene escalates to the next dosage in Phase 1 trial Leading charity, Parkinson’s UK, will provide £2.9m (~$5m) to fund a Phase 2 study of the Pharmaxis (ASX:P...

The ASX will open lower on Thursday Wall Street slipped for the fourth consecutive day Europe’s inflation hits a new record Local shares are set to open lower today. At 8am AEST, the ASX 200 September futures contract is pointing down by...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((BHP)) - BHP Group ((CGF)) - Challenger ((GMG)) - Goodman Group ((JHX)) - James Hardie Industries ((JRV)) - Jervois Global ((360)) - Life360 ((PXS)) - Pharmaxis ((SEK)) -...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

ShareCafePXS – Morgans rates the stock as Speculative Buy Morgans initiates coverage of commercial stage drug development company Pharmaxis with a Speculative Buy rating and $0.58 target price. Cancers and inflammatory conditions are the ta...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Australian company Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment has commenced dosing in patients with established scars.

The collaboration with the research team led by Professor Fiona Wood AM has dosed the first patients in a trial of 50 patients with established scars.

Pharmaxis (ASX:PXS) says it welcomes new drug development grants from the federal government awarding NHMRC funding to two research teams to advance work they are conducting with two of the company's discoveries.

“Together, our work aims to support commercialisation of new treatment approaches for pancreatic cancer and various skin diseases, which we hope will deliver significant benefits for patients,” PXS CEO Garry Phillps said.

Pharmaxis (PXS) receives drug development grants from the Australian government, funding two research teams to advance the company’s work Associate Professor Thomas Cox from the Garvan Institute of Medical Research has been awarded with $8...

US stocks fell hard as Fed outlines rate cut plan There were more investor jitters over interest rates overnight, as minutes from the Fed’s December meeting showed that policymakers had outlined plans to lift rates sooner than expected, and...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Pharmaxis (PXS) has announced its oversubscribed share purchase plan (SPP) has raised $2.6 million The company says it will accept all eligible applications and issue around 24.6 million fully paid shares, which will rank equally with exis...

The clinical-stage drug development company opted to increase its raise target from A$2 million after receiving eligible applications for A$2.585 million worth of shares.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Among a range of factors for the outperform recommendation, Taylor Collison cites the company’s two FDA-approved respiratory products, Bronchitol for cystic fibrosis and the asthma diagnostic Aridol, which are expected to be profitable on a...

Welcome to the Market Herald Deal Room for this Friday, where we review the week in capital raising. Emyria (EMD) shares soared more than 60 per cent on news Andrew “Twiggy” Forrest’s private investment group Tattarang had invested $5 mi...

The capital raise is part of its move to bolster its balance sheet as it enters a transformational 12 months with clinical trials of its lead drug PXS-5505 in cancer.

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica...

“Pharmaxis is entering a transformational 12 months with two clinical studies expected to deliver safety and efficacy data in diseases with high unmet need and addressable markets of over $1 billion by the end of 2022," says CEO.

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

Pharmaxis is tapping investors to raise $9.2 million, with the capital set to support the next phase of clinical trials for its cancer and scar treatment candidates.

IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 202...

The ASX closed down again today in spite of resources and tech gaining over 1%. The ASX 200 fell 0.24%, closing at 7,434 points. Despite the gains in resources and tech most other sectors fell with financials, property and energy retreating...

“The rapid progression from the compelling pre-clinical work presented for the first time in August to a successful IND submission is very encouraging and we look forward to concluding arrangements for the commencement of the dose escalatio...

The ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index which is up by 0.03%. The US FDA has cleared Pharmaxis (ASX:PXS)’s Investigational New Drug application (IND) for a trial of its lead drug,...

The US FDA has cleared Pharmaxis' (ASX:PXS) Investigational New Drug (IND) application for a trial of PXS‐5505 in patients with hepatocellular carcinoma.